Curis (CRIS) Publishes Preclinical Data for CUDC-305 in Clinical Cancer Research
More News related to CRIS
- Curis to Present at Merriman Curhan Ford's Investor Summit 2009
- Curis (CRIS) Posts Q3 Loss of $0.06, In-Line with Estimates
- Curis Reports Third Quarter 2009 Financial Results
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Curis to Present at the Oppenheimer 20th Annual Healthcare Conference
Curis, Inc. (NASDAQ: CRIS) today announced that preclinical data related to CUDC-305, the company's Heat Shock Protein 90 inhibitor, was published online this week in Clinical Cancer Research. The paper, entitled "CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacological properties for cancer therapy," will also be published in the print version of this journal shortly.
The publication reports that, in addition to potent antitumor efficacy against a broad range of cancers in preclinical tumor models as both a single agent and in combination, CUDC-305 exhibits promising pharmacological features in several areas, including high oral bioavailability, tumor selectivity, blood-brain barrier penetration, and extended retention of the compound in tumor tissue relative to normal tissue.
More from the release.
Related Categories
Corporate NewsStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
